勃林格殷格翰的能倍乐在国内上市了吗？

Has similar affinity for five choline receptors (M1-M5). It dilates bronchial smooth muscle by binding to M3 receptors on smooth muscle. This effect is competitive and reversible. Respimat is a long-acting anticholinergic drug developed by Boehringer Ingelheim. So, has Boehringer Ingelheim’s Respimat been launched in the country?

Respimat has been launched in the country. The recommended dose of Respimat Tiotropium Bromide Spray is: Respimat is effective 24 hours a day, so it only needs to be used once a day, and if possible, at the same time every day. Spray twice with each use.

Boehringer Ingelheim is a pharmaceutical company dedicated to human biopharmaceutical chemistry and animal health products. It is also the world's largest privately held pharmaceutical company. Boehringer Ingelheim's main research areas include: immune and respiratory diseases, cardiovascular and metabolic diseases, central nervous system diseases, and tumors. Boehringer Ingelheim has a complete biopharmaceutical industry chain, from genetic engineering of cells to manufacturing, and commercial production of off-the-shelf medicines for external industrial customers.

Clinical trial data shows that the therapeutic effect of Respimat is significant. The successful development of this drug is good news for many patients. However, patients cannot blindly take this drug for treatment. Before receiving treatment with Respimat, patients should go to the hospital for a detailed examination and strictly follow the doctor's diagnosis and treatment recommendations.

During the treatment period, patients should not increase or decrease the dosage of drugs without authorization. Only correct use of drugs will help the condition. When a bronchial asthma attack occurs, antispasmodic and anti-inflammatory measures should be taken into consideration, airway mucus plugs should be removed, the respiratory tract should be kept open, and secondary infection should be prevented.

It is currently used to treat dyspnea caused by airway obstructive diseases such as bronchial asthma, chronic bronchitis, wheezing bronchitis, and emphysema. It is especially suitable for patients who need to take long-term adrenergic β2 receptor agonists and patients with nocturnal asthma. However, Respimat is a once-daily maintenance bronchodilator and cannot be used as a rescue treatment for acute episodes of bronchospasm.